LncRNA RBPMS-AS1 promotes NRGN transcription to enhance the radiosensitivity of glioblastoma through the microRNA-301a-3p/CAMTA1 axis

Wenyang Li, Yan Cui, Wenjia Ma, Ming Wang, Yang Cai, Yugang Jiang

ARTICLE INFO

Keywords:
Glioblastoma
LncRNA RBPMS-AS1
microRNA-301a-3p
CAMTA1
NRGN
Radiosensitivity

ABSTRACT

Objective: Glioblastoma (GBM) is the most frequent brain malignancy with high incidence, and long noncoding RNAs (lncRNAs) exert functions in GBM. In this research, we focused on the capabilities of lncRNA RBPMS-AS1 in radiosensitivity of GBM.

Methods: RBPMS-AS1 and CAMTA1 expression levels were determined in GBM tissues and cells. StarBase v3.0 database was searched for predicting miRNAs that simultaneously bound to RBPMS-AS1 and CAMTA1. pcDNA3.1-RBPMS-AS1, pcDNA3.1-CAMTA1, miR-301a-3p mimic, or pcDNA3.1-RBPMS-AS1/pDNA3.1-CAMTA1 and miR-301a-3p mimic were transfected into GBM cells to test radiosensitivity, cell proliferation and apoptosis. The interactions of miR-301a-3p with RBPMS-AS1 and CAMTA1, as well as CAMTA1 and NRGN, were confirmed. In vivo imaging technology was utilized to detect tumor growth in orthotopic xenograft tumors, and Ki67 expression was tested in intracranial tumors.

Results: RBPMS-AS1 and CAMTA1 levels were reduced in GBM tissues and cells. miR-301a-3p had a binding site with both RBPMS-AS1 and CAMTA1 and it was the most significantly-upregulated one. Upregulation of RBPMS-AS1 or CAMTA1 enhanced the radiosensitivity and cell apoptosis while suppressing proliferation of GBM cells. Conversely, miR-301a-3p overexpression diminished the radiosensitivity and cell apoptosis while inducing proliferation of GBM cells. Overexpression of RBPMS-AS1 or CAMTA1 reversed the effects of overexpressed miR-301a-3p in GBM cells. Mechanistically, RBPMS-AS1 enhanced CAMTA1 expression in GBM cells through sponging miR-301a-3p, and CAMTA1 promoted NRGN expression. In animal experiments, overexpressed RBPMS-AS1 inhibited tumor growth and the positive expression of Ki67 both before and after radiation therapy.

Conclussion: RBPMS-AS1 promotes NRGN transcription through the miR-301a-3p/CAMTA1 axis and enhances the radiosensitivity of GBM.

Introduction

Glioblastoma (GBM) is the most frequent and aggressive type of primary malignant tumor in the central nervous system [1]. This disease is identified with specific characteristics of diffuse infiltration and local invasion into the surrounding brain tissues, significant cellular proliferation, robust angiogenesis, genomic instability, resistance to apoptosis, as well as a tendency for necrogenesis [2]. At present, considerable studies in GBM therapeutics are intended to develop vaccines or drugs so as to target the pivotal molecules for preventing this disease [3]. The prognosis for GBM patients remains grim even with significant advances in imaging methods, surgical techniques, achievements in radiation medicine, enhancing availability of targeted drugs and chemotherapeutics, as well as better understanding of the tumor biology [4]. For this regard, although GBM is a relatively rare type of cancer in terms of its incidence, it has disproportionately high ratios of cancer-related mortality and morbidity [5]. Thus, a clear unmet need is significant to improve the outcome and radiosensitivity for GBM patients.

Long noncoding RNAs (lncRNAs) modulate diverse oncogenes and tumor suppressor genes from the aspect of translation, transcription, protein localization, and function [6]. Additionally, lncRNAs are also
implicated in the epigenetic control of DNA repair, cell differentiation and apoptosis [7, 8]. Recently, the abnormal expression of lncRNAs could play a role in the biological functions of human tumors, including glioma [9, 10]. The exploration of lncRNAs is essential for diagnosis and treatment of GBM. Evidence has shown that lncRNA RBPMS-AS1 is involved in the process of lung adenocarcinoma (LUAD) and cervical cancer [11, 12]. Yet, the specific actions of RBPM-AS1 in GBM cells still needs further exploration. In the past several years, lncRNAs have been disclosed as competing endogenous RNAs (ceRNAs) to control mRNA expression via competitively sequestering certain miRs in many human cancers [13]. miRs are transcribed from DNA and participate in gene expression regulation in the small RNA molecule form [14]. Evidence has highlighted that the deregulation of miRs contributes to chemoresistance in cancers [15]. Previously, several articles have demonstrated that miR-301a-3p is an onco-miR in many types of cancers, such as breast cancer [16], stomach cancer [17], and pancreatic cancer [18]. Especially, miR-301a-3p has been also found in the development of glioma [19], but how miR-301a-3p is involved in glioma progression remains undetermined. Calmodulin-binding transcription activator 1 (CAMTA1) belongs to a recently-characterized protein family which is designated as calmodulin-binding transcription activators [20]. CAMTA1 is homozygously deleted in gliomas [21, 22] and is the only gene within the smallest region of overlap at 1p36 in this entity [23]. In a previous study, CAMTA1 was found to be regulated by miR-17 and miR-9/9(*) in glioblastoma stem cells [24]. Moreover, it has also been previously reported that NRGN is lowly expressed in GBM [25], and it is positively regulated by LINC00641 in GBM [26]. Based on the aforementioned evidences, this study was conducted to elucidate the functions of the RBPM-AS1/miR-301a-3p/CAMTA1/NRGN axis in the progression and radiosensitivity of GBM.

Materials and methods

Ethics statement

Written informed consents were acquired from all patients before experiments. The protocol of this research was confirmed by the Ethics Committee of Second Xiangya Hospital of Central South University and based on the ethical principles for medical research involving human subjects of the Helsinki Declaration. Additionally, the animal experiment got the approval of the animal ethics committee of Second Xiangya Hospital of Central South University. All animal experiments abide by the rules, regulations and operational specifications of experimental animal management and related ethical requirements for experimental animals.

Patients and clinical samples

The paired GBM tissues and corresponding normal tissues were harvested from 38 patients who had been confirmed with primary GBM in Second Xiangya Hospital of Central South University between October 2016 and June 2019. Those patients who received radiotherapy or chemotherapy before surgery were excluded from our study.

Cell culture and irradiation

Four GBM cell lines (U251, U87, LN229 and A172) and normal human astrocytes (NHA) were available from Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China). GBM and NHA cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum in an incubator at 37°C with 5% CO2. For irradiation, U251 and U87 cells were seeded onto a 100-mm culture dishes at 1 × 106 cells per dish and then cultured for 24 h, before irradiation at room temperature with 0, 2, 4, 6 and 8 Gy laboratory X-ray by an irradiation apparatus (2100 C/D, VARIAN, CA, USA).

Cell transfection

Before transfection, GBM cells were placed in a 96-well plate. RBPM-AS1 and CAMTA1 were amplified by polymerase chain reaction (PCR) and inserted into an empty vector (pcDNA3.1, Invitrogen, Carlsbad, CA, USA) to construct pcDNA3.1/RBPMS-AS1 and pcDNA3.1/CAMTA1 vectors. The pcDNA3.1/RBPMS-AS1 (2 μg), pcDNA3.1/CAMTA1 (2 μg), and miR-301a-3p mimic (100 nmol) were transfected into U87 and U251 cells, respectively. The cells were cultured in the 96-well plates until the cell confluence reached 70%–80%, and then transfected as per the protocols of Lipofectamine 2000. The cells upon 48 h transfection were collected for subsequent experiments.

3-(4,5-dimethylthiazol-2-yl)–2,5-diphenyl tetrazolium bromide (MTT) assay

U87 and U251 cells were exposed to 0, 2, 4, 6 and 8 Gy of X-ray irradiation, and the transfected cells were seeded onto a 96-well plate at 4000 cells per well. MTT assay was implemented for assessing the cell viability referring to the product instructions. In short, phosphate buffered saline (PBS) in each well was appended with 10 μL of 5 mg/mL MTT reagent and then incubated for 4 h at 37°C. Afterwards, each well was supplemented with 150 μL of dimethylsulfoxide to dissolve the precipitate. Lastly, the measurement of the optical density (OD) value was carried out with a microplate reader at 490 nm.

Colony formation assay

The colony formation assay was implemented for evaluating the cell proliferation in different groups. In brief, the cells after transfection were seeded onto a 6-well plate, irradiated with 6 Gy, and then cultured for 10 days. More than fifty naturally-formed colonies were subjected to fixing with 75% ethanol and staining with 0.5% (w/v) crystal violet solution (Sigma-Aldrich, St. Louis, MO, USA), followed by the observation of the number of colonies by using a microscope (Wetzlar, Leica Microsystems, Germany), and photographing by a digital camera and analyzing by an Image J 2.0 version software.

Flow cytometry

The cell apoptosis was determined by Annexin V/propidium iodide (PI) Apoptosis Detection Kit (KeyGEN Biotech, Nanjing, China). In short, the transfected cells were seeded onto a 6-well plate and irradiated with 6 Gy, washed once with pre-cooled PBS, and added with 300 μL of 1× binding buffer to suspend the cells. Subsequently, the cells were appended with 5 μL of Annexin V-fluoresceine isothiocyanate solution and 5 μL of PI solution, and reacted for 15 min in darkness. After passing through a 300-mesh sieve, the cell apoptosis was tested on a flow cytometer (Becton Dickinson; San Jose, CA, USA).

Reverse transcription quantitative polymerase chain reaction (RT-qPCR)

Total RNA in the tissues and cultured cells was extracted by TRIzol (Thermo Fisher Scientific, MA, USA) as per the manufacturer’s requirements. Next, the reverse transcription of RNA into cDNA was realized by Reverse Transcription System (Promega, WI, USA). The expression levels of target genes were tested by a LightCycler 480 fluorescence quantitative PCR instrument (Roche, IN, USA). The reaction conditions were carried out based upon the instructions of the fluorescent quantitative PCR kit (SYBR Green PCR kit, Takara Bio, Inc., Otsu, Japan); 95°C pre-denaturation for 5 min, and next, with 40 cycles of 95°C denaturation for 10 s, 60°C annealing for 10 s and 72°C extension for 20 s. Glyceraldehyde phosphate dehydrogenase (GAPDH) and U6 were selected as the standardized controls. Data were analyzed using 2–ΔΔCt method and the primer sequences were shown in Table 1.
Table 1

| Name       | Primer sequence                        |
|------------|----------------------------------------|
| miR-301a-3p| F: 5′-ACACTCCAGCTGGCGACATGATGTGCTC-3′  |
|            | R: 5′-CTCAAGTCTTGGTGTTGA-3′            |
| U6         | F: 5′-CAGCTTCAGCAAAAATTGGGT-3′         |
|            | R: 5′-AAGGCTTCACAAATTTGCT-3′          |
| RBPMS-AS1  | F: 5′-GAAGAGGAGAACACCCCGAG-3′         |
|            | R: 5′-TGAGTTAGCAGGAAATTTGGTG-3′       |
| NRGN       | F: 5′-CCAGGAGTCTGCACCTGTTT-3′         |
|            | R: 5′-CTTTTTCCACATCCAGGGGT-3′         |
| CAMTA1     | F: 5′-ATCCTCACAGGACAAATTTCC-3′        |
|            | R: 5′-AGTTTCAGGTGCAATCTACAG-3′        |
| GAPDH      | F: 5′-GTCACTGCGGACGTGACCT-3′          |
|            | R: 5′-GTCTAGGCAAAATTGGTTG-3′          |

Note: miR, microRNA; CAMTA1, calmodulin-binding transcription activator 1; NRGN, neurogranin; GAPDH, glyceraldehyde phosphate dehydrogenase; F, forward; R, reverse.

Western blot analysis

The extraction of proteins were from cells and tissues of each group and the protein concentration was measured with the application of the bicinchoninic acid protein kit. After that, the protein samples were separated on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel, transferred onto membranes (300 mA) and blocked by 5% skimmed milk powder for 1 hour. Next, the membranes were incubated with horseradish peroxidase-conjugated secondary antibody (Abcam) at 37 °C. The biotinylated miR-301a-3p-WT or miR-301a-3p-Mut or negative control (NC) were utilized for the treatment of U251 and U87 cells. Then streptavidin-coated magnetic beads (Ambion, Austin, TX, USA) were supplemented in the cell lysate. The enrichment of RBPMS-AS1 and CAMTA1 was conducted by RT-qPCR with the pull down of the biotin-coupled RNA complex.

Animal

Twenty-four specific pathogen-free grade (SPF) BALB/c nude mice (4–6 weeks old, 16–20 g, male) from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China) were randomly selected into our experiment. The bedding, drinking water, particulate feed, and other articles in contact with the animal were treated with autoclaved sterilization. All experimental animals were raised in a SPF-level aseptic layer under the conditions of a constant temperature of (22–26 °C) and a constant humidity of (55 ± 5%).

An orthotopic xenograft model in nude mice

U251 cells were infected with a lentivirus containing a Luciferase and a green fluorescent protein (GFP), and the flow cytometry was utilized to screen the stably-expressing GFP-Luc cell lines. The nude mice were randomly assigned into a Vector group (transfection of pcDNA3.1 in U251-GFP-Luc cell suspension) and a pcDNA3.1-RBPMS-AS1 group (transfection of pcDNA3.1-RBPMS-AS1 in U251-GFP-Luc cell suspension). Upon 24-hour transfection of U251-GFP-Luc cells, the nude mice were anesthetized by intraperitoneal injection with pentobarbital sodium (60 mg/kg). After anesthesia, the head skin of the nude mice was disinfected by conventional iodophor, and then the nude mice were fixed in the middle of the triangle with a stereotactic instrument. The head skin was cut vertically along 3 mm to the right of the longitudinal midline of the head and at the junction with the two ears to expose the skull. The skull of the nude mouse was opened using a dental drill at 2 mm to the right of the bilateral eye and ear junction. The transfected or untransfected U251-GFP-Luc cell suspension (3 × 10^6) was absorbed using a sterilized microsample sampler. The needle was inserted along the bore for approximately 3 mm, and then backed for 1 mm, and the rats were slowly injected with 100 μL cell suspension. After injection, the boreholes were closed with bone wax, the skin incision was stitched, the wound was disinfected, and the nude mice were placed back to the cage for feeding after recovery from anesthesia.

Nude mouse irradiation

After the orthotopic xenograft model was successfully established, the nude mice with two groups (Vector group and pcDNA3.1-RBPMS-AS1 group) determined by live imaging scan were randomly divided into radiotherapy and non-radiotherapy groups, namely all orthotopic xenograft models into four groups: non-radiotherapy or radiotherapy RBPMS-AS1 group (RBPMS-AS1-IR or RBPMS-AS1-non-IR group) and non-radiotherapy or radiotherapy Vector group (Vector-IR or Vector-non-IR group). Whole cranial irradiation of nude mice was performed 3 times at a bolus dose of 2 Gy each time, for a total of 6 Gy, and the irradiation was completed within a week. The live imaging of nude mice was performed again after radiotherapy.

Live imaging scan

After 21 days and 42 days, the nude mice were intraperitoneally injected with luciferase substrate (substrate concentration: 15 mg/mL, 10 μL/g), and the change of luminescence signal was observed on a small animal Live Imager (IVIS Spectrum, Caliper, USA) to analyze the brain tumorigenesis and growth status. Nude mice were subsequently anesthetized and euthanized, and the skull was dissected to preserve the tissues for reserve.
Translational Oncology 15 (2022) 101282

Immunohistochemistry

Tumor tissue samples for in vivo experiments were first fixed with 4% paraformaldehyde, and then embedded and cut with paraffin. Continuous 4-μm thick sections were selected for immunohistochemical analysis using anti-Ki67 antibody (Santa Cruz Biotechnology, Dallas, TX).

Statistical analysis

Unless otherwise stated, all experiments were repeated three times. All data analyses were conducted using SPSS 18.0 software (IBM Corp., Armonk, NY, USA) and GraphPad Prism 6.0 (GraphPad Software Inc.). Data were reported as mean ± standard deviation. The t-test was performed for comparisons between two groups, and one-way analysis of variance (ANOVA) was conducted for comparisons among multiple groups and Tukey’s multiple comparisons test was used for pairwise comparisons after one-way ANOVA. p value less than 0.05 was indicative of statistically significant difference.

Results

RBPM-S1 enhances the radiosensitivity of GBM

The copy number variation of RBPM-S1 is positively related to the overall survival of lung adenocarcinoma patients [12], while it has not been studied in GBM. In our research, we performed RT-qPCR to detect the RBPM-S1 expression level in GBM tissues and the corresponding normal tissues, and the results of which showed that decreased RBPM-S1 expression was observed in GBM tissues in comparison to normal tissues (Fig. 1A). In addition, GBM cells (A172, LN229, U251 and U87) also had lower expression levels of RBPM-S1 than NHA cells, while the RBPM-S1 expression level in U251 and U87 cells was relatively lower, thus we selected U251 and U87 cells for the subsequent experiments (Fig. 1B).

Additionally, RBPM-S1 expression level was detected in U251 and U87 cells post exposure to varying doses of irradiation. Similarly, in U251 and U87 cells, RBPM-S1 expression level decreased with increasing dose of irradiation treatment (Fig. 1C), and the reduction of RBPM-S1 expression was more significant with the irradiation dose of 6 Gy and 8 Gy. These data indicate that RBPM-S1 may be related to the radiosensitivity of GBM.

For the purpose of exploring the effect of RBPM-S1 on the...
radiosensitivity of GBM, we transfected pcDNA3.1-RBPMS-AS1 into U251 and U87 cells, and the RT-qPCR method verified the successful transfection (Fig. 1D). According to the findings of MTT assay, we found that RBPMS-AS1 overexpression enhanced the radiosensitivity of U251 and U87 cells (Fig. 1E). In addition, the results of colony formation assay and flow cytometry indicated that when RBPMS-AS1 was overexpressed, the inhibition of cell proliferation resulted from the increased radiation dose was further enhanced (Fig. 1F), and the apoptosis caused by the increase in radiation dose was also further enhanced (Fig. 1G). Therefore, we conclude that RBPMS-AS1 promotes radiosensitivity of GBM.

Upregulation of CAMTA1 enhances radiosensitivity of GBM

The Genecards website shows that CAMTA1 contains a transcription factor immunoglobulin domain, ankyrin repeats, as well as calmodulin-binding IQ motifs. CAMTA1 acts as a tumor inhibitory gene in gliomas [21], and there is a report revealing that CAMTA1 is acted as a transcription factor to activate the transcription of cardiac hormone sodium A (NPPA), and induces anti-proliferation effects in glioma cells [24]. In our research, we performed RT-qPCR to detect the CAMTA1 expression level in GBM tissues and the corresponding normal tissues, which revealed that decreased CAMTA1 expression was found in GBM tissues versus normal tissues (Fig. 2A). In addition, GBM cells (A172, LN229, U251 and U87) also exhibited lower expression levels of CAMTA1 than
NHA cells based on the results of RT-qPCR and Western blot assays (Fig. 2B,C). Subsequently, we transfected pcDNA3.1-CAMTA1 into U251 and U87 cells, and the RT-qPCR and Western blot assay verified the successful transfection (Fig. 2D,E). From the findings of MTT assay, colony formation assay and flow cytometry, we could see that CAMTA1 overexpression enhanced the radiosensitivity of U251 and U87 cells (Fig. 2F), promoted the suppression of cell proliferation and also the apoptosis caused by the increased radiation dose (Fig. 2G,H). These findings indicate that CAMTA1 enhances the radiosensitivity of GBM.

**RBPMS-AS1 enhances the expression of CAMTA1 in GBM cells through sponging miR-301a-3p**

Recently, emerging studies have reported the role of lncRNA in the competitive endogenous RNA (ceRNA) network. Therefore, whether there was a relationship between RBPMS-AS1 and CAMTA1 raised our interest. Based on this, we speculated that RBPMS-AS1 may affect CAMTA1 expression in GBM cells through the ceRNA mechanism. Furthermore, whether there was a relationship between RBPMS-AS1 and CAMTA1 in GBM intrigued us. We observed that overexpressed RBPMS-AS1 could stimulate the CAMTA1 expression in U251 and U87 cells (Fig. 3A,B). This indicates that RBPMS-AS1 regulates the expression of CAMTA1 in GBM cells.

According to the prediction of starBase v3.0, 17 miRNAs were found to simultaneously bind to RBPMS-AS1 and CAMTA1 (Fig. 3C). Among these 17 miRNAs, only miR-34c-5p, miR-4295, miR-301a-3p, and miR-301b-3p were up-regulated in GBM cells, and miR-301a-3p was up-regulated most significantly (Fig. 3D). Therefore, we selected miR-301a-3p for the follow-up experiments.

Subsequently, we investigated whether miR-301a-3p was involved in the mechanism of ceRNA. First, we used a bioinformatics tool to predict the binding sequence of miR-301a-3p and RBPMS-AS1 or miR-301a-3p and CAMTA1 (Fig. 3E). Through a dual luciferase reporter assay, it was verified that relative to the control, the luciferase activity of cells inserted with RBPMS-AS1-WT or CAMTA1-WT was significantly reduced when miR-301a-3p was overexpressed, while the luciferase activity of RBPMS-AS1-Mut or CAMTA1-Mut was not affected by miR-301a-3p mimic (Fig. 3F). Importantly, RNA pull-down assay (Fig. 3G) suggested that versus the control, both RBPMS-AS1 and CAMTA1 enrichment was elevated in U251 and U87 cells introduced with biotinylated miR-301a-3p-WT, while the cells introduced with biotinylated miR-301a-3p-Mut failed to enrich RBPMS-AS1 and CAMTA1, suggesting the interaction of miR-301a-3p with RBPMS-AS1 and CAMTA1. Additionally, in cells with miR-301a-3p mimic treatment, CAMTA1 expression was significantly reduced (Fig. 3H-I).
expression levels were decreased, which was subsequently restored by upregulation of RBPMS-AS1 (Fig. 3H,I). These data imply that RBPMS-AS1 increases the expression of CAMTA1 in GBM cells through sponging miR-301a-3p.

**RBPMS-AS1 inhibits GBM cell proliferation and radiotherapy resistance through miR-301a-3p/CAMTA1 axis**

For further exploring whether RBPMS-AS1 inhibited GBM cell proliferation and radiotherapy resistance through the miR-301a-3p/CAMTA1 axis, we transfected mimic NC, miR-301a-3p mimic, or miR-301a-3p mimic + pcDNA3.1-RBPMS-AS1/pDNA3.1-CAMTA1 simultaneously in U251 and U87 cells, respectively. The results of RT-qPCR and Western blot assay indicated that elevated expression level of miR-301a-3p and reduced RBPMS-AS1 and CAMTA1 expression levels were found in GBM cells upon miR-301a-3p mimic treatment, while the effects of miR-301a-3p mimic on the miR-301a-3p, RBPMS-AS1 and CAMTA1 expression levels were counteracted in GBM cells in response to further transfection with pcDNA3.1-RBPMS-AS1; however, the expression level of CAMTA1 increased significantly, while the expression levels of RBPMS-AS1 and miR-301a-3p did not change in GBM cells further transfected with pcDNA3.1-CAMTA1 (Fig. 4A,B). Meanwhile, the functional experiments suggested that restoration of miR-301a-3p diminished the radiosensitivity of U251 and U87 cells (Fig. 4C), weakened the restriction of cell proliferation and also weakened the apoptosis caused by the increased radiation dose (Fig. 4D,E). However, GBM cells exposed to radiation showed promoted radiosensitivity, reduced proliferation, and enhanced apoptosis when RBPMS-AS1 or CAMTA1 was upregulated despite overexpressed miR-301a-3p (Fig. 4C-E). The above results reveal that RBPMS-AS1 restricts GBM cell proliferation and radiotherapy resistance through the miR-301a-3p/CAMTA1 axis.

**CAMTA1 promotes NRGN expression**

The JASPAR database shows that CAMTA1 can be used as a transcription factor to bind to the promoter region of the downstream gene NRGN to regulate NRGN expression (Fig. 5A). Interestingly, an in-vitro experiment has suggested that NRGN has an anti-proliferative effect on GBM cells [26]. We, therefore, analyzed whether CAMTA1 also activated the expression of NRGN in GBM cells. U251 and U87 cells were treated with a plasmid expressing CAMTA1-WT or a mutant lacking a DNA binding domain, in which NRGN expression was analyzed by RT-qPCR (Fig. 5B). There was an increased NRGN expression level in cells transfected with CAMTA1-WT plasmid, while the NRGN expression in cells transfected with CAMTA1-Mut plasmid was slightly increased, compared with cell transfection with empty plasmid.

Furthermore, because RBPMS-AS1 and miR-301a-3p could regulate CAMTA1 expression in GBM cells, we tested NRGN expression in cells upon transfection of pcDNA3.1-RBPMS-AS1 or the simultaneous

---

*Fig. 4. RBPMS-AS1 restricts GBM cell proliferation and radiotherapy resistance through the miR-301a-3p/CAMTA1 axis.*
A. RBPMS-AS1, miR-301a-3p and CAMTA1 expression levels in transfected U251 and U87 cells in each group were tested by RT-qPCR. B. CAMTA1 expression level in transfected U251 and U87 cells in each group were tested by Western blot assay. C. The survival conditions of transfected U251 and U87 cells in each group under 0, 2, 4, 6 and 8 Gy X-ray irradiation were measured by MTT assay. D. The proliferation conditions of transfected U251 and U87 cells in each group at 0 and 6 Gy X-ray irradiation were detected by colony formation assay. E. The apoptosis rates of transfected U251 and U87 cells in each group at 0 and 6 Gy X-ray irradiation were tested by flow cytometry. \( N = 3, \ast, p < 0.05, \ast\ast, p < 0.01, \ast\ast\ast, p < 0.001. \) One-way ANOVA was used for comparisons among multiple groups and Tukey’s multiple comparisons test was used for pairwise comparisons after one-way ANOVA.
Transfection of pcDNA3.1-RBPMS-AS1 and miR-301a-3p mimic. It was found that there was an elevation in NRGN expression in GBM cells upon transfection of pcDNA3.1-RBPMS-AS1, while the expression of which was reversed in GBM cells upon the simultaneous transfection of pcDNA3.1-RBPMS-AS1 and miR-301a-3p mimic (Fig. 5C,D). The above results imply that NRGN expression in GBM cells may be achieved through this regulatory network of the RBPMS-AS1/miR-301a-3p/CAMTA1 axis.

RBPMS-AS1 inhibits the formation and radiosensitivity of in situ tumors in vivo

With the aim to further clarify the anti-tumor effect of RBPMS-AS1 in vivo, we conducted an orthotopic xenograft model and radiotherapy experiment in nude mice. pCDNA3.1 or pCDNA3.1-RBPMS-AS1 was transfected in U251 cells, and the cell suspension was prepared upon 24-hour transfection, which was then transplanted into nude mice. Live imaging results in nude mice showed that the fluorescence intensity in the Vector-non-IR group was significantly stronger than that in the RBPMS-AS1-non-IR group; the fluorescence intensity was further decreased in the Vector-IR group compared to the Vector-non-IR group; and the fluorescence intensity was further decreased in the RBPMS-AS1-IR group compared to the RBPMS-AS1-non-IR group (Fig. 6A). The results of immunohistochemistry indicated that before radiotherapy, RBPMS-AS1 overexpression inhibited the positive expression of Ki67, and RBPMS-AS1 overexpression further inhibited the positive expression of Ki67 after radiotherapy (Fig. 6B). The above results indicated that RBPMS-AS1 overexpression inhibited the transplanted tumor growth of U251 cells in nude mice and further inhibited the growth of transplanted tumors in nude mice after receiving the same dose of radiotherapy. The findings of this research suggest that RBPMS-AS1 overexpression may be related to the greater sensitivity of U251 cells to radiotherapy in animals.

Discussion

GBM is difficult to treat for involving the genetic and chromosomal aberrations, which causes tumor cells invade aggressively and proliferate uncontrollably [3]. Standard treatments include surgical resection, external beam radiation, and chemotherapy containing varied inhibitors, while no known curative therapy has been found [27, 28]. Hence, it is crucial to explore more effective therapeutic agents that can prevent the growth of GBM cells and the mechanisms underlying the acquisition of radiosensitivity in GBM.

A growing number of articles have illustrated that dysregulated lncRNAs are able to participate in diverse tumors, including glioma [29, 30]. For instance, Liu et al. have found that lncRNA OIP5-AS1 controls the biological processes in glioma via mediating microRNA (miR)-367–3p/CEBPA [31]. Zheng et al. have stated that lncRNA CRNDE induces glioma progression via modulating miR-384/PIWIL4/STAT3 signaling [32]. In our research, we detected the expression level of RBPMS-AS1/miR-301a-3p/CAMTA1 axis.
overexpressed RBPMS-AS1 could stimulate the CAMTA1 expression level in U251 and U87 cells, implying the association of CAMTA1 and RBPMS-AS1 in GBM cells. CAMTA1 is of great importance in diverse human cancers, acting as a tumor inhibitive gene in neuroblastomas, gliomas and colorectal cancers [23, 33, 34]. In accord with RBPMS-AS1, CAMTA1 was also proposed a regulatory factor of radiosensitivity in GBM in our research. In a prior research, CAMTA1 overexpression has been found to suppress cell colony formation and growth rate, and also restrict in vivo growth in nude mice, strengthening the role of CAMTA1 as a tumor inhibitor candidate [35]. Strikingly, CAMTA1 has been implied to have an anti-tumor activity in neuroblastoma cells, which functions the same in many neural tumors [35]. Furthermore, CAMTA1 leads to a strong diminish of colony formation, implying that CAMTA1 is an anti-tumor factor in GBM [24].

Subsequently, we elucidated whether miR-301a-3p was involved in ceRNA mechanism, and the data implied that RBPMS-AS1 increased CAMTA1 expression in GBM cells through sponging miR-301a-3p. Meanwhile, the functional experiments suggested that upregulation of miR-301a-3p diminished the radiosensitivity and apoptosis, and increased proliferation of GBM cells. However, the functions of upregulated miR-301a-3p on the malignant features of GBM were counteracted by upregulation of RBPMS-AS1 and CAMTA1, revealing that RBPSMS-AS1 restricted GBM cell proliferation and radiotherapy resistance through the miR-301a-3p/CAMTA1 axis. Numerous studies have suggested that miR-301a-3p could induce the malignant phenotypes of cancer cells. The findings in Xia et al. have confirmed that the restoration of miR-301a-3p can stimulate the gemcitabine cytotoxicity towards human pancreatic ductal adenocarcinoma cells [36]. Another study has demonstrated that miR-301a-3p is increased in patients with treatment resistance, and reduced in patients responsive to the treatment, supporting that miR-301a-3p is an indicator in epileptic patients to determine treatment resistance [37]. In line with our findings, the reduced miR-301a-3p expression in tumor tissues are capable of identifying a subgroup of GBM patients that had been treated with regorafenib with profitable benefit [19].

Moreover, the JASPAR database predicted that CAMTA1 could be used as a transcription factor to bind to the promoter region of the downstream gene NRGN to regulate NRGN expression. Recently, the significance of NRGN has been recognized in several brain-related diseases, including schizophrenia, Parkinson’s disease and Alzheimer disease [38–40]. Previously, Yokota et al. have reported that NRGN is downregulated in GBM tissues [25]. Also, an in-vitro experiment has disclosed that NRGN has an anti-proliferative effect on GBM cells [26]. In the present article, we also implied that RBPMS-AS1 and miR-301a-3p might regulate the NRGN expression in GBM cells through modulating CAMTA1.

In previous researches, YAP and TAZ are two proteins often associated with the CAMTA1 function [41, 42]. The Hippo pathway transcriptional coactivators YAP/TAZ have been considered as therapeutic targets [43]. Evidence has shown that YAP and TAZ are upregulated in epidermal growth factor receptor (EGFR)-amplified/mutant human GBMs, and the downregulation of YAP and TAZ inhibit proliferation and elicit apoptosis in EGFR-amplified/mutant GBM cells [44]. Lei Zhang et al.
have stated that depletion of TAZ induces radiation-induced growth arrest, and the β-catenin destruction complex activation could promote radiation-induced TAZ suppression and growth arrest in GBM tumor cells [45]. Due to time and funding issues, we failed to explore the regulatory mechanisms of RBPM-AS1, CAMTA1, and YAP and TAZ in GBM, which would be the research point in our further study. Additionally, the regulation of radiosensitivity in GBM by the RBPM-AS1/miR-301a-3p/CAMTA1 axis necessitates more extensive animal experiments.

Together, our data suggest that RBPM-AS1 promotes NRGN transcription through the miR-301a-3p/CAMTA1 axis and enhances the radiosensitivity of GBM. Understanding the function of RBPM-AS1 may help unearth effective therapeutic strategies for GBM patients. Further dissection of RBPM-AS1 downstream signaling and understanding of mechanisms modulating RBPM-AS1 will be the next research focal point.

Authors’ contribution

JYG and LWY conceived the ideas. JYG and LWY designed the experiments. LWY and C. Yan performed the experiments. LWY; MWJ and WM analyzed the data. JYG and LWY provided critical materials. C. Yan; WM and C. Yang wrote the manuscript. JYG supervised the study. All the authors have read and approved the final version for publication.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

Thanks for all the contributors and participants.

Funding

This research was funded by the grants from Hunan Provincial Natural Science Youth Foundation (Grant No. 2019J50873); Hunan Provincial Health Commission Project Fund (Grant No. 20214040152) and Hunan Provincial Science & Technology Department Planning Project (Grant No. 2018SK21213).

Supplementary materials

Supplementary material associated with this article can be found in the online version, at doi:10.1016/j.tranon.2021.101282.

References

[1] H.S. Nguyen, S. Shabani, A.J. Awdal, M. Kaushal, N. Doan, Molecular Markers of Therapy-Resistant Glioblastoma and Potential Strategy to Combat Resistance, Int. J. Mol. Sci. 19 (6) (2018).
[2] A. Fathi Kazerooni, S. Bakas, H. Saligheh Rad, C. Davatzikos, Imaging signatures of glioblastoma molecular characteristics: a radiogenomics review, J. Magn. Reson. Imaging 52 (1) (2020) 54-69.
[3] M.N. Abbas, S. Kaur, H. Cui, Therapeutic potential of natural products in epigenetic alterations, Clin. Transl. Oncol. 22 (7) (2020) 2104–2106.
[4] D. Schraivogel, L. Weinmann, D. Beier, G. Tabatabai, A. Eichner, J.Y. Zhu, et al., CAMTA1, a novel antitumor gene, regulates proliferation and the cell cycle in glioma by inhibiting AKT phosphorylation, Cell. Signal. 79 (2021), 108852.
[5] K. Ichimura, A.P. Vogiazianou, L. Liu, D.M. Pearson, L.M. Backlund, K. Plant, et al., 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumors and homozygously deleted in a subset of glioblastomas, Oncogene 27 (14) (2008) 2097–2108.
[6] V. Barbashina, P. Salazar, E.C. Holland, M.K. Rosenblum, M. Ladanyi, Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene, Clin. Cancer Res. 11 (3) (2005) 1119–1126.
[7] S. Deguchi, K. Katsushima, A. Hatanaka, K. Shinjo, F. Ohka, T. Wakabayashi, et al., RUNX3 regulates vimentin expression via miR-30a during epithelial-mesenchymal transition in gastric cancer cells, J. Cell. Mol. Med. 18 (4) (2014) 610–623.
[8] X. Xia, K. Zhang, G. Gen, T. Jiang, J. Cao, K. Huang, et al., MicroRNA-30a-3p promotes pancreatic cancer progression via negative regulation of SMAD4, Oncotarget 6 (25) (2015) 21046–21053.
[9] B. Gong, P. Wang, et al., A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafinib, Neuro. Oncol. 23 (2) (2021) 264–276.
[10] Z. He, C. Yang, Y. He, B. Gong, C. Yin, J. Feng, et al., CARTAM1, a novel antitumor gene, regulates proliferation and the cell cycle in glioma by inhibiting AKT phosphorylation, Cell. Signal. 79 (2021), 108852.
[11] Z. He, C. Yang, Y. He, B. Gong, C. Yin, J. Feng, et al., CARTAM1, a novel antitumor gene, regulates proliferation and the cell cycle in glioma by inhibiting AKT phosphorylation, Cell. Signal. 79 (2021), 108852.
[12] S. Deguchi, K. Katsushima, A. Hatanaka, K. Shinjo, F. Ohka, T. Wakabayashi, et al., RUNX3 regulates vimentin expression via miR-30a during epithelial-mesenchymal transition in gastric cancer cells, J. Cell. Mol. Med. 18 (4) (2014) 610–623.
[13] X. Liu, J. Zheng, Y. Xue, H. Yu, W. Gong, P. Wang, et al., PIWIL3/OIP5-AS1/miR-301a-3p/CAMTA1 axis promotes pancreatic cancer progression via negative regulation of SMAD4, Oncotarget 6 (25) (2015) 21046–21053.
[14] A. Sanchez-Mejias, Y. Tay, Competing endogenous RNA networks: tying the knot, Nat. Rev. Cancer 18 (1) (2018) 5–18.
[15] A. Fathi Kazerooni, S. Bakas, H. Saligheh Rad, C. Davatzikos, Imaging signatures of glioblastoma molecular characteristics: a radiogenomics review, J. Magn. Reson. Imaging 52 (1) (2020) 54-69.
[16] A.R. Boileau, F.D. Miller, Changes in spectral sensitivity of multiplier phototubes resulting from changes in temperature, Appl. Opt. 6 (7) (1967) 1179–1182.
[36] X. Xia, K. Zhang, G. Luo, G. Cen, J. Cao, K. Huang, et al., Downregulation of miR-301a-3p sensitizes pancreatic cancer cells to gemcitabine treatment via PTEN, Am. J. Transl. Res. 9 (4) (2017) 1886–1895.

[37] J. Wang, L. Tan, L. Tan, Y. Tian, J. Ma, C.C. Tan, et al., Circulating microRNAs are promising novel biomarkers for drug-resistant epilepsy, Sci. Rep. 5 (2015) 10201.

[38] M.I. Kester, C.E. Temanisen, D.L. Crimmins, E.M. Herries, J.H. Ladenson, P. Scheltens, et al., Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease, JAMA Neurol. 72 (11) (2015) 1275–1280.

[39] A.O. Koob, G.M. Shaked, A. Bender, A. Bisquertt, E. Rockenstein, E. Masliah, Neurogranin binds alpha-synuclein in the human superior temporal cortex and interaction is decreased in Parkinson’s disease, Brain Res. 1591 (2014) 102–110.

[40] K. Ohi, R. Hashimoto, Y. Yasuda, M. Fukumoto, H. Yamamori, S. Umeda-Yano, et al., Influence of the NRGN gene on intellectual ability in schizophrenia, J. Hum. Genet. 58 (10) (2013) 700–705.

[41] J.M. Lamar, V. Motilal Nehru, G. Weinberg, Epithelioid Hemangioendothelioma as a Model of YAP/TAZ-Driven Cancer: insights from a Rare Fusion Sarcoma, Cancers (Basel) 10 (7) (2018).

[42] C.N. Seavey, A.V. Pobbati, A. Hallett, S. Ma, J.P. Reynolds, R. Kanai, et al., WWTR1 (TAZ)-CAMTA1 gene fusion is sufficient to dysregulate YAP/TAZ signaling and drive epithelioid hemangioendothelioma tumorigenesis, Genes Dev. 35 (7–8) (2021) 512–527.

[43] Z. Liu, Y. Wei, L. Zhang, P.P. Yee, M. Johnson, X. Zhang, et al., Induction of store-operated calcium entry (SOCE) suppresses glioblastoma growth by inhibiting the Hippo pathway transcriptional coactivators YAP/TAZ, Oncogene 38 (1) (2019) 120–139.

[44] K. Vigneswaran, N.H. Boyd, S.Y. Oh, S. Lallani, A. Boucher, S.G. Neill, et al., YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma, Clin. Cancer Res. 27 (5) (2021) 1553–1569.

[45] L. Zhang, F. Cheng, Y. Wei, L. Zhang, D. Guo, B. Wang, et al., Inhibition of TAZ contributes radiation-induced senescence and growth arrest in glioma cells, Oncogene 38 (15) (2019) 2788–2799.